An ongoing series of thought-provoking articles on issues of the day from Regeneron’s leaders.
Discover how Regeneron has broken down communication walls between preclinical and clinical researchers to orchestrate optimal strategies for getting a drug from bench to bedside.
The story behind Regeneron's first Costimulatory Bispecific Clinical Trial
Our long-term commitment to fostering the next generation of scientists
Discover how Regeneron scientists are tapping into
their long-standing expertise in growth factor
biology to better
understand their potential for treating chronic pain. Learn more.
Regeneron scientists discuss their motivations for
studying diabetic retinopathy (DR) and how their job was to
not only
establish a new treatment approach, but also shifting the mindset around the disease.
Regeneron listens and learns from those who live with rare diseases to help bring meaningful change where there are frequently few or no treatments. Learn more.
Niall O'Leary, Site Head of Industrial Operations and Product Supply in Ireland, shares his story of how he helped to take an American company and make it work in Ireland by embodying shared values.
David Weinreich, head of Global Clinical Development, discusses the value of thoughtful innovation in biotech and how Regeneron works to put patients first.
Hala Mirza, SVP of Corporate Communications and Citizenship at Regeneron, discusses corporate responsibility and explains Regeneron's own responsibility strategy. Read more.
Our President & CSO, George Yancopoulos, discusses why we must recognize the next generation of scientists as heroes, and how we can support their efforts.
Regeneron is speeding up novel gene discovery by working with founder populations such as the Amish community. This makes it possible for scientists to identify genetic anomalies with a much smaller sample size. Learn more.
The global community faces several questions about disease, food security, and climate change to name a few. How do we overcome these? One way is to support the Regeneron Science Talent Search. These passionate, skilled young people bring fresh perspectives to significant global problems.
As physician-scientists and biotech leaders, we have grown increasingly concerned about the current dialogue on the biopharma industry, which tends to focus on short-term issues. But, we fear there are even more important longer-term issues at stake...
Regeneron’s head of Research & Development, Neil Stahl, discusses why we are researching treatments we hope no one will ever need. By harnessing the power of our technology, we are working on medicines to treat infectious diseases like Ebola.
How do you spark a scientific revolution in genomics? Pair lightning-fast, computational pattern recognition with an unprecedented amount of health data. The Regeneron Genetics Center® is leveraging the power of artificial intelligence and machine learning to mine robust genetic and real-world heath data.
